Perceptive Advisors Llc - Feb 20, 2024 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role: Director
Signature: /s/ Joseph Edelman for Perceptive Life Sciences Master Fund Ltd., By: Perceptive Advisors LLC, its investment manager, by Joseph Edelman, its managing member
Stock symbol: CERE
Transactions as of: Feb 20, 2024
Transactions value $: $0
Form type: 4
Date filed: 2/21/2024, 04:54 PM
Previous filing: Feb 20, 2024
Next filing: Apr 3, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CERE	Common Stock	Gift	$0	-170K	-100%	$0.00^*	0	Feb 20, 2024	See footnote	F1
holding	CERE	Common Stock						10.8M	Feb 20, 2024	See footnote	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Prior to the disposition reported on this Form 4, the securities were directly held by C2 Life Sciences, LLC ("C2"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of C2, and Mr. Edelman is the managing member of the Advisor.
F2	The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). The Advisor serves as the investment manager of Master Fund. Mr. Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

Content

Prior to the disposition reported on this Form 4, the securities were directly held by C2 Life Sciences, LLC ("C2"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of C2, and Mr. Edelman is the managing member of the Advisor.

The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). The Advisor serves as the investment manager of Master Fund. Mr. Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.